Homepage - PharmaSignal

PharmaSignal Explainers — How Pharma Deals Really Work

Why Peak-Sales Models Survive Long After Their Credibility Breaks

February 9, 2026

PharmaSignal Explainers

How Local Pricing Autonomy Gets Engineered Out at Deal Sign-Off

By sagarmahajan2886@gmail.comDecember 29, 20250

PharmaSignal Explainers

Why “Approved” Filings Unravel After Central Teams Disengage

By PharmaSignal News DeskDecember 18, 20250

Trending

M&A and Licensing

RallyBio Merges with Avenzo to Target Rare Diseases

2 Mins Read

M&A and Licensing

Servier acquires Edgewise’s muscular dystrophy tablet

3 Mins Read

M&A and Licensing

Lilly acquires three biotechs to boost vaccine research

3 Mins Read

M&A and Licensing

Sun Pharma acquisition signals global expansion ambitions

3 Mins Read

Deals in focus

M&A and Licensing

Novo Nordisk Acquires Akero for $5.2 Billion

M&A and Licensing

Bristol Myers and Hengrui form $15.2 billion alliance

M&A and Licensing

Contingent Value Rights Boost Biotech Deals

M&A and Licensing

Novartis licenses RNA medicine from Arrowhead in $200M deal

markets

Market Access

Trump Administration Unveils Medicare Drug Prices

November 28, 2025By PharmaSignal News Desk

Medicare Drug Prices for 15 drugs unveiled, saving $8.5 billion, a 36% reduction.

Market & Financials

Moderna H5 Influenza Vaccine Secures New Funding

RallyBio Merges with Avenzo to Target Rare Diseases

Servier acquires Edgewise’s muscular dystrophy tablet

Weekly digest

Deal of the Month

Deal of the Month: Deal Signals to note

A senior BD execution signal from this month’s most instructive pharma deal.